| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | 2.677 | 6.311 | 1.676 | 10.229 | 7.008 | 7.184 | 8.788 | 11.733 | 17.182 |
| Total Income - EUR | - | 2.680 | 6.314 | 1.676 | 10.229 | 7.008 | 7.193 | 8.788 | 11.733 | 17.182 |
| Total Expenses - EUR | - | 226 | 802 | 662 | 4.141 | 2.270 | 3.813 | 13.560 | 15.299 | 15.194 |
| Gross Profit/Loss - EUR | - | 2.454 | 5.512 | 1.014 | 6.087 | 4.739 | 3.381 | -4.772 | -3.566 | 1.988 |
| Net Profit/Loss - EUR | - | 2.374 | 5.323 | 964 | 5.781 | 4.551 | 3.276 | -4.866 | -3.684 | 1.473 |
| Employees | - | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Neuroval Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | 104 | 0 | 0 | 94 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | - | 2.394 | 6.708 | 7.747 | 13.639 | 18.088 | 21.436 | 229 | 935 | 2.810 |
| Inventories | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | - | 0 | 405 | 12 | 0 | 0 | 0 | 110 | 0 | 0 |
| Cash | - | 2.394 | 6.304 | 7.735 | 13.639 | 18.088 | 21.436 | 119 | 935 | 2.810 |
| Shareholders Funds | - | 2.418 | 7.700 | 8.522 | 14.137 | 18.420 | 21.287 | -4.813 | -8.482 | -6.962 |
| Social Capital | - | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | - | 80 | 53 | 0 | 210 | 38 | 823 | 5.093 | 9.534 | 9.823 |
| Income in Advance | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Neuroval Med Srl